Cooperative Agreement U01CA281433
Award Date
9/19/24
Completion Date
8/31/29
Dollars Obligated
$401K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Cooperative Agreement
Place of Performance
Seattle, WA 98195, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
This federal Project Grant award from the National Cancer Institute (under CFDA 93.394 - Cancer Detection and Diagnosis Research program) provides $671,072 to the University of Washington to develop a novel ultra-miniaturized "picoliter thin-layer chromatography (PTLC) chip" and supporting instrumentation. The goal is to create an integrated microdevice that can measure malignant lipid signaling in single cells from clinical samples with enhanced sensitivity and throughput compared...
The National Cancer Institute awarded a $721,836 Cooperative Agreement (U01CA289564) to the University of Washington from May 1, 2024 to April 30, 2029 under the Cancer Biology Research program (CFDA 93.396). The award will fund research to investigate how apoptotic (programmed cell death) cells promote the spread of cancer through mechanisms involving platelet recruitment, coagulation, and myeloid cell reprogramming at metastatic sites. This work aims to elucidate fundamental processes by...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is funding research at the University of Washington to develop a pharmacoproteomics platform that can predict drug response in liver cancer. The $599,745 award, with a project period from April 2024 to March 2026, aims to optimize a predictive model that links kinome activity in liver cancer cell lines to kinase inhibitor drug response. The research will evaluate the...
This Cooperative Agreement award of $356,850 from the National Cancer Institute (NCI), under the Cancer Treatment Research grant program (CFDA 93.395), aims to establish pre-analytical sample processing guidelines to enable maximal reproducibility for functional testing outcomes in liquid biopsy-based cancer research and clinical testing.
The project, led by Oregon Health & Science University (OHSU), focuses on characterizing the pre-analytical steps involved in blood and bone marrow...
This federal Project Grant award for $661,831 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to create the Human Cancer Metabolome Atlas (HCMA). The key products and services to be delivered under this 5-year project include:
Analyzing a large-scale collection of over 2,000 patient-derived xenograft (PDX) tumor samples using mass spectrometry-based metabolomics to characterize the cancer metabolome. The PDX models have already been...
The National Cancer Institute awarded a $407,113 Project Grant (CFDA 93.396 - Cancer Biology Research) to Trustees of Boston University for the development of bio-orthogonal mid-infrared photothermal imaging technology to study cancer metabolism. This 3-year award, running from September 1, 2024 to August 31, 2027, aims to: 1) build a library of nitrile-based probes to sense molecular events in cancer cells; 2) develop nitrile-tagged small molecules to measure nutrient metabolism; and 3)...
The University of Texas Southwestern Medical Center was awarded a $348,500 Cooperative Agreement by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The funding will support the development of a platform called RIBO-SNAP to assay the dynamics of ribosome biogenesis in living cells, enabling the identification of new genes and small molecules that inhibit protein synthesis in cancer cells. The project also involves developing a...
The Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Adeptrix Corp, a biotechnology company, to initiate development of a multiplexed, protein-based assay called PATH10 that will simultaneously measure protein targets across 10 major cell signaling pathways involved in cancer. This $295,230 award, with a period of performance from July 1, 2024 to December 31, 2024, will focus initially on the RAF-MEK-ERK pathway, which has a...
The National Cancer Institute awarded a $990,771 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Binary Genomics, Inc. located in Madison, CT. The purpose of this 2-year award, which began on September 17, 2024, is to develop and clinically validate a circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapy. The assay aims to provide a broadly applicable solution for tracking patient response to immunotherapies without...